Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
EBMT 2022
We recently spoke with Jacob Soumerai (@MassGeneralNews), who shared the latest updates in cellular therapy for CLL, highlighted a real-world evidence analysis of liso-cel, & outlined potential strategies to improve upon CD19-directed #CARTCell therapy.
Click to watch:
🎥…
Latest updates in cell therapy for CLL: real-world insights and strategies to improve CAR-T therapy
Jacob Soumerai, MD, Massachusetts General Hospital, Boston, MA, discusses the latest updates in cellular therapy for c...
twitter.com
🚨 LAST CHANCE TO REGISTER for our ASH 2025 #MPN Highlights webinar taking place TOMORROW
Join Prof. @harrisoncn1, Dr Francesca Palandri & Dr John Mascarenhas for the Post ASH 2025 Highlights: MPN Webinar🩸🔬
🗓️ Thursday 29 January | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00…
Welcome! You are invited to join a webinar: Post-ASH 2025 MPNs highlights webinar. After register...
Join us to watch leading MPNs experts present summaries on the most significant abstracts from ASH 2025 followed b...
twitter.com
Did you miss last week's podcast?🎙️
Listen here: 👉https://ow.ly/j46i50Y14vO 👈
Featuring @yasminabaza1 and Yannis Valtis (@MSKCancerCenter), who discuss the management and prevention of differentiation syndrome in APL.
#HemOnc #Leukemia
🎥 @AlexBataller of @MDAndersonNews shares the results of a Phase I/II trial evaluating oral decitabine-cedazuridine in combination with venetoclax in patients with HR-MDS or CMML:
➡️
#MDSsm #CMML #RareDisease #Leusm #Leukemia #ASH25 #CTSM #TrialUpdate
Oral decitabine-cedazuridine in combination with venetoclax in treatment-naïve HR-MDS or CMML
In this video, Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses t...
ow.ly
Are you interested in hearing about the PROMISE study, which screened over 30,000 individuals for monoclonal gammopathies?🩸
Make sure you don't forget to watch our interview from #ASH25 with @SabineWaelAllam of @DanaFarber:
🎥 ➡️
#SmolderingMyeloma… https://twitter.com/i/web/status/2016209786405065135
The PROMISE study: screening over 30,000 individuals for monoclonal gammopathies
In this interview, Sabine Allam, MD, Dana Farber Cancer Institute, Boston, MA, discusses the results of the PROMISE ...
ow.ly
EBMT 2022
We recently spoke with Jacob Soumerai (@MassGeneralNews), who shared the latest updates in cellular therapy for CLL, highlighted a real-world evidence analysis of liso-cel, & outlined potential strategies to improve upon CD19-directed #CARTCell therapy.
Click to watch:
🎥…
Latest updates in cell therapy for CLL: real-world insights and strategies to improve CAR-T therapy
Jacob Soumerai, MD, Massachusetts General Hospital, Boston, MA, discusses the latest updates in cellular therapy for c...
twitter.com
🚨 LAST CHANCE TO REGISTER for our ASH 2025 #MPN Highlights webinar taking place TOMORROW
Join Prof. @harrisoncn1, Dr Francesca Palandri & Dr John Mascarenhas for the Post ASH 2025 Highlights: MPN Webinar🩸🔬
🗓️ Thursday 29 January | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00…
Welcome! You are invited to join a webinar: Post-ASH 2025 MPNs highlights webinar. After register...
Join us to watch leading MPNs experts present summaries on the most significant abstracts from ASH 2025 followed b...
twitter.com
Did you miss last week's podcast?🎙️
Listen here: 👉https://ow.ly/j46i50Y14vO 👈
Featuring @yasminabaza1 and Yannis Valtis (@MSKCancerCenter), who discuss the management and prevention of differentiation syndrome in APL.
#HemOnc #Leukemia
🎥 @AlexBataller of @MDAndersonNews shares the results of a Phase I/II trial evaluating oral decitabine-cedazuridine in combination with venetoclax in patients with HR-MDS or CMML:
➡️
#MDSsm #CMML #RareDisease #Leusm #Leukemia #ASH25 #CTSM #TrialUpdate
Oral decitabine-cedazuridine in combination with venetoclax in treatment-naïve HR-MDS or CMML
In this video, Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses t...
ow.ly
Are you interested in hearing about the PROMISE study, which screened over 30,000 individuals for monoclonal gammopathies?🩸
Make sure you don't forget to watch our interview from #ASH25 with @SabineWaelAllam of @DanaFarber:
🎥 ➡️
#SmolderingMyeloma… https://twitter.com/i/web/status/2016209786405065135
The PROMISE study: screening over 30,000 individuals for monoclonal gammopathies
In this interview, Sabine Allam, MD, Dana Farber Cancer Institute, Boston, MA, discusses the results of the PROMISE ...
ow.ly
